Beta-amyloid (Abeta) deposition is pathognomic for Alzheimer's disease (AD), but may occur in normal elderly people without apparent cognitive effect.
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Women may expect to spend more than a third of their lives after menopause. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Age and female sex are risk factors for dementia, and menopause is associated with cognitive dysfunction. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review recounts the definitions and research evidence supporting the multifaceted roles of neuroinflammation in the injured brain following trauma. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The benefits of regular physical activity (PA) on disease prevention and treatment outcomes have been recognized for centuries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Use of pharmacological treatments is one possible modifiable risk factor for cognitive disorders. 5 key findings →
Design: case-control study Participants: 282,858 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This manuscript is the second part of a two-part description of the current status of understanding of the network function of the brain in health and disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A comprehensive outcome monitoring system to monitor the quality and safety of care and variation for HCP recipients was developed. 1 key finding →
Design: cross-sectional Participants: 68 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The foundation of preventive cardiology relies on the assessment of cardiovascular (CV) risk using scores based on traditional risk factors. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Long sleep was associated with reduced overall cognitive function (β ± standard error = -0.25 ± 0.07, p < 0.001), with strongest effects in those with depressive symptoms using (-0.74 ± 0.30, p = 0.017) and not using antidepressants (-0.60 ± 0.26, p = 0.024). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent trials of repetitive transcranial magnetic stimulation (rTMS) have reported encouraging results for improving or stabilizing cognition in patients diagnosed with Alzheimer dementia. 5 key findings →
Participants: 523 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is the most common type of dementia worldwide. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Prior MR imaging studies, primarily at 1.5T, established hippocampal atrophy as a biomarker for Alzheimer disease. 3T MR imaging offers a higher contrast and signal-to-noise ratio, yet distortions and intensity uniformity are harder to control. 4 key findings →
Participants: 166 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
47/100
Astrocyte infection with human immunodeficiency virus (HIV) is considered rare, so astrocytes are thought to play a secondary role in HIV neuropathogenesis. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At baseline, participants were aged 70-95 years (mean: 75.2 ± 4.3), with 54% being women. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 403 participants (mean age 56.4 ± 5.7 years, 62.5% female), the median number of dementia risk factors was 5.0; hyperlipidaemia (92.5%), low cognitive activity (72.5%), obesity (57.6%), and hypertension (52.7%) were the most prevalent. 5 key findings →
Design: cross-sectional Participants: 403 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, statin drugs appear to be safe for use in the vast majority of patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Four clusters were identified: least disadvantaged (Class 1: 31.5% men; 30.6% women), most disadvantaged (Class 2: 20.2% men; 19.4% women), high social support with Class 1 features (Class 3: 22.2% men; 24.1% women), and high social support with Class 2 features (Class 4: 26.1% men; 25.7% women). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the sample was 63 years (Q1, Q3, 56, 68); 56% were women. 5 key findings →
Participants: 15,180 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
46/100
In the fully adjusted model, the cumulative odds ratios (OR) are 1.28 (95% confidence interval [CI]: 1.25–1.31) for any dementia, 1.44 (95% CI: 1.36–1.53) for Alzheimer’s disease and 1.65 (95% CI: 1.48–1.83) for vascular dementia, associated with per unit increase in annual cumulative flooding exposure over lag 0–6 years. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher glial fibrillary acidic protein (GFAP) was associated with higher depressive symptoms. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a major public health concern in societies with increasingly ageing populations. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We anticipate that transcranial alternating current stimulation will be a well-tolerated treatment, with no serious side effects and with considerable short- and long-term cognitive improvements. 2 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
People with intellectual disabilities are at a higher risk for experiencing behavioral, emotional, and psychiatric problems in comparison with the general population. 2 key findings →
Participants: 255 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →